A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Clinical trial NCT01725100 · COMPLETED
Trial details
- NCT number
- NCT01725100
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-02-05
- Primary completion
- 2015-01-30
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.